Cargando…

A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies

Therapeutic monoclonal antibodies (mAbs) have a propensity to host a large number of chemical and enzymatical modifications that need to be properly assessed for their potential impact on target binding. Traditional strategies of assessing the criticality of these attributes often involve a laboriou...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhengqi, Yan, Yuetian, Wang, Shunhai, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559042/
https://www.ncbi.nlm.nih.gov/pubmed/36224723
http://dx.doi.org/10.1080/19420862.2022.2133674
_version_ 1784807574967681024
author Zhang, Zhengqi
Yan, Yuetian
Wang, Shunhai
Li, Ning
author_facet Zhang, Zhengqi
Yan, Yuetian
Wang, Shunhai
Li, Ning
author_sort Zhang, Zhengqi
collection PubMed
description Therapeutic monoclonal antibodies (mAbs) have a propensity to host a large number of chemical and enzymatical modifications that need to be properly assessed for their potential impact on target binding. Traditional strategies of assessing the criticality of these attributes often involve a laborious and low-throughput variant enrichment step prior to binding affinity measurement. Here, we developed a novel competitive binding-based enrichment strategy followed by mass spectrometry analysis (namely, competitive binding-MS) to achieve high-throughput evaluation of potential critical quality attributes in therapeutic mAbs. Leveraging the differences in target binding capability under competitive binding conditions, the criticality of multiple mAb attributes can be simultaneously evaluated by quantitative mass spectrometry analysis. The utility of this new workflow was demonstrated in three mAb case studies, where different post-translational modifications occurring within the complementarity-determining regions were successfully interrogated for their impact on antigen binding. As this workflow does not require prior enrichment (e.g., by forced degradation or liquid chromatography fractionation) of the variants, it is particularly valuable during the mAb candidate developability assessment, where fast turn-around time is highly desired to assist candidate selection. Abbreviations: ACN: acetonitrile; ADCC: antibody-dependent cell-mediated cytotoxicity; AEX: anion exchange chromatography; bsAb: bispecific antibody; CDC: complement-dependent cytotoxicity; CDR: complementarity-determining region; CML: carboxymethylation; CQA: critical quality attribute; DDA: data-dependent acquisition; DMSO: dimethyl sulfoxide; DTT: dithiothreitol; FA: formic acid; Fab: Fragment antigen-binding; FcRn: neonatal Fc receptor; HC: heavy chain; HIC: hydrophobic interaction chromatography; IAA: iodoacetamide; IEX: ion exchange chromatography; LC: light chain; mAb monoclonal antibody; msAb: monospecific antibody; MS: mass spectrometry; PBS: phosphate-buffered saline; pI: isoelectric point; PTM: post-translational modification; SCX: strong cation exchange chromatography; SEC: size exclusion chromatography; SPR: surface plasmon resonance; XIC: extracted ion chromatography.
format Online
Article
Text
id pubmed-9559042
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-95590422022-10-14 A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies Zhang, Zhengqi Yan, Yuetian Wang, Shunhai Li, Ning MAbs Report Therapeutic monoclonal antibodies (mAbs) have a propensity to host a large number of chemical and enzymatical modifications that need to be properly assessed for their potential impact on target binding. Traditional strategies of assessing the criticality of these attributes often involve a laborious and low-throughput variant enrichment step prior to binding affinity measurement. Here, we developed a novel competitive binding-based enrichment strategy followed by mass spectrometry analysis (namely, competitive binding-MS) to achieve high-throughput evaluation of potential critical quality attributes in therapeutic mAbs. Leveraging the differences in target binding capability under competitive binding conditions, the criticality of multiple mAb attributes can be simultaneously evaluated by quantitative mass spectrometry analysis. The utility of this new workflow was demonstrated in three mAb case studies, where different post-translational modifications occurring within the complementarity-determining regions were successfully interrogated for their impact on antigen binding. As this workflow does not require prior enrichment (e.g., by forced degradation or liquid chromatography fractionation) of the variants, it is particularly valuable during the mAb candidate developability assessment, where fast turn-around time is highly desired to assist candidate selection. Abbreviations: ACN: acetonitrile; ADCC: antibody-dependent cell-mediated cytotoxicity; AEX: anion exchange chromatography; bsAb: bispecific antibody; CDC: complement-dependent cytotoxicity; CDR: complementarity-determining region; CML: carboxymethylation; CQA: critical quality attribute; DDA: data-dependent acquisition; DMSO: dimethyl sulfoxide; DTT: dithiothreitol; FA: formic acid; Fab: Fragment antigen-binding; FcRn: neonatal Fc receptor; HC: heavy chain; HIC: hydrophobic interaction chromatography; IAA: iodoacetamide; IEX: ion exchange chromatography; LC: light chain; mAb monoclonal antibody; msAb: monospecific antibody; MS: mass spectrometry; PBS: phosphate-buffered saline; pI: isoelectric point; PTM: post-translational modification; SCX: strong cation exchange chromatography; SEC: size exclusion chromatography; SPR: surface plasmon resonance; XIC: extracted ion chromatography. Taylor & Francis 2022-10-12 /pmc/articles/PMC9559042/ /pubmed/36224723 http://dx.doi.org/10.1080/19420862.2022.2133674 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Report
Zhang, Zhengqi
Yan, Yuetian
Wang, Shunhai
Li, Ning
A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies
title A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies
title_full A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies
title_fullStr A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies
title_full_unstemmed A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies
title_short A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies
title_sort competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559042/
https://www.ncbi.nlm.nih.gov/pubmed/36224723
http://dx.doi.org/10.1080/19420862.2022.2133674
work_keys_str_mv AT zhangzhengqi acompetitivebindingmassspectrometrystrategyforhighthroughputevaluationofpotentialcriticalqualityattributesoftherapeuticmonoclonalantibodies
AT yanyuetian acompetitivebindingmassspectrometrystrategyforhighthroughputevaluationofpotentialcriticalqualityattributesoftherapeuticmonoclonalantibodies
AT wangshunhai acompetitivebindingmassspectrometrystrategyforhighthroughputevaluationofpotentialcriticalqualityattributesoftherapeuticmonoclonalantibodies
AT lining acompetitivebindingmassspectrometrystrategyforhighthroughputevaluationofpotentialcriticalqualityattributesoftherapeuticmonoclonalantibodies
AT zhangzhengqi competitivebindingmassspectrometrystrategyforhighthroughputevaluationofpotentialcriticalqualityattributesoftherapeuticmonoclonalantibodies
AT yanyuetian competitivebindingmassspectrometrystrategyforhighthroughputevaluationofpotentialcriticalqualityattributesoftherapeuticmonoclonalantibodies
AT wangshunhai competitivebindingmassspectrometrystrategyforhighthroughputevaluationofpotentialcriticalqualityattributesoftherapeuticmonoclonalantibodies
AT lining competitivebindingmassspectrometrystrategyforhighthroughputevaluationofpotentialcriticalqualityattributesoftherapeuticmonoclonalantibodies